Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004859 · ClinicalTrials.gov registry record · Phase 3
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 589
- Enrollment target
NCT00004859: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00004859 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 589 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004859, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 589 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly diagnosed stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. It is not yet known if combination chemotherapy plus radiation therapy is more effective with or without thalidomide.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 589 participants |
| Start Date | 2000-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004859
The ClinicalTrials.gov registry entry for NCT00004859 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 589 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT00004859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004859 about?
NCT00004859 is a clinical study titled "Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer". This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly diagnosed stage III non-small cell lung cancer. Drugs used in chemotherap...
What is the current status of trial NCT00004859?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 589 participants. The study started on 2000-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00004859?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00004859?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.